

Dan V Iosifescu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3598594/dan-v-iosifescu-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

10,632
citations

50
h-index

100
g-index

206
ext. papers

12,545
ext. citations

5.5
avg, IF

6.04
L-index

#	Paper	IF	Citations
185	Imbalance between default mode and sensorimotor connectivity is associated with perseverative thinking in obsessive-compulsive disorder.. <i>Translational Psychiatry</i> , 2022 , 12, 19	8.6	0
184	Relationships between interoceptive sensibility and resting-state functional connectivity of the insula in obsessive-compulsive disorder.. <i>Cerebral Cortex</i> , 2022 ,	5.1	1
183	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes.. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022 , 48674221077619	2.6	0
182	Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.. <i>American Journal of Psychiatry</i> , 2022 , appiajp21080800	11.9	6
181	A systematic review and network meta-analysis of carbon dioxide provocation in psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2021 , 143, 508-515	5.2	0
180	Correlation between S100B and severity of depression in MDD: A meta-analysis. <i>World Journal of Biological Psychiatry</i> , 2021 , 1-11	3.8	2
179	Affective and somatic symptom clusters in depression and their relationship to treatment outcomes in the STAR*D sample.. <i>Journal of Affective Disorders</i> , 2021 , 300, 469-469	6.6	
178	Influences on childhood depressive symptoms: The effects of trauma and distress tolerance across age and sex groups. <i>Journal of Affective Disorders</i> , 2021 , 283, 373-376	6.6	2
177	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2021 , 178, 437-446	11.9	6
176	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Focus (American Psychiatric Publishing)</i> , 2021 , 19, 222-242	1.1	2
175	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. <i>Depression and Anxiety</i> , 2021 , 38, 114-123	8.4	3
174	Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. <i>Translational Psychiatry</i> , 2021 , 11, 88	8.6	9
173	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. <i>European Neuropsychopharmacology</i> , 2021 , 49, 122-132	1.2	4
172	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. <i>Psychiatry Research</i> , 2021 , 305, 114194	9.9	
171	Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression. <i>European Neuropsychopharmacology</i> , 2021 , 53, 89-100	1.2	0
170	Are Electroencephalogram-Derived Predictors of Antidepressant Efficacy Closer to Clinical Usefulness?. <i>JAMA Network Open</i> , 2020 , 3, e207133	10.4	0
169	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). <i>Neuropsychopharmacology</i> , 2020 , 45, 1656-1663	8.7	23

168	A randomized proof-of-mechanism trial applying the fast-fail approach to evaluating opioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , 2020 , 26, 760-768	50.5	63
167	Plasma Neuronal and Glial Markers and Anterior Cingulate Metabolite Levels in Major Depressive Disorder: A Pilot Study. <i>Neuropsychobiology</i> , 2020 , 79, 214-221	4	9
166	Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. <i>Brain</i> , 2020 , 143, 701-710	11.2	25
165	The buildup of an urge in obsessive-compulsive disorder: Behavioral and neuroimaging correlates. <i>Human Brain Mapping</i> , 2020 , 41, 1611-1625	5.9	7
164	Glutamate Modulators in Major Depressive Disorder 2020 , 169-174		
163	Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	25
162	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. <i>Journal of Affective Disorders</i> , 2020 , 273, 131-137	6.6	3
161	Dimensions of interoception in obsessive-compulsive disorder. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2020 , 27, 100584-100584	1.7	2
160	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Frontiers in Psychiatry</i> , 2020 , 11, 595584	5	37
159	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020 , 25, 1592-1603	15.1	125
158	Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. <i>Molecular Psychiatry</i> , 2020 , 25, 1323-1333	15.1	26
157	Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. <i>Psychophysiology</i> , 2020 , 57, e13356	4.1	12
156	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020 , 260, 131-139	6.6	14
155	Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta-analysis. <i>Journal of Neuroscience Research</i> , 2020 , 98, 950-963	4.4	14
154	Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. <i>Chronic Stress</i> , 2019 , 3, 2470547019877880	3	0
153	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. <i>Acta Neuropsychiatrica</i> , 2019 , 31, 230-234	3.9	1
152	Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2019 , 44, 1812-1819	8.7	21
151	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. <i>Archives of Clinical Neuropsychology</i> , 2019 , 34, 539-547	2.7	2

150	Protein Biomarkers in Major Depressive Disorder: An Update. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1140, 585-600	3.6	2
149	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. <i>Journal of Psychiatric Research</i> , 2019 , 110, 166-171	5.2	24
148	Reported Side Effects, Weight and Blood Pressure, After Repeated Sessions of Transcranial Photobiomodulation. <i>Photobiomodulation, Photomedicine, and Laser Surgery</i> , 2019 , 37, 651-656	2.8	12
147	Neural Predictors of the Antidepressant Placebo Response. <i>Pharmaceuticals</i> , 2019 , 12,	5.2	1
146	Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 3255-3272	3.1	9
145	Effects of transcranial photobiomodulation with near-infrared light on sexual dysfunction. <i>Lasers in Surgery and Medicine</i> , 2019 , 51, 127-135	3.6	12
144	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. <i>Depression and Anxiety</i> , 2019 , 36, 235-243	8.4	21
143	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. <i>Journal of Affective Disorders</i> , 2018 , 230, 56-64	6.6	28
142	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 200-206	1.7	6
141	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , 2018 , 11, 75-84	5.1	14
140	A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 3-11	5.8	38
139	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. <i>Nature Reviews Drug Discovery</i> , 2018 , 18, 82-84	64.1	33
138	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2018 , 30, 297-305	3.9	8
137	A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 336-343	1.7	
136	The Influence of Depression on the Psychometric Properties of the Maslach Burnout Inventory-Human Services Survey: A Cross-Sectional Study With Nursing Assistants. <i>Frontiers in Psychiatry</i> , 2018 , 9, 695	5	9
135	DNA methylation levels are associated with CRF receptor antagonist treatment outcome in women with post-traumatic stress disorder. <i>Clinical Epigenetics</i> , 2018 , 10, 136	7.7	21
134	Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. <i>Photomedicine and Laser Surgery</i> , 2018 , 36, 634-646		39
133	Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2018 , 84, 563-573	7.9	22

132	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. <i>Npj Digital Medicine</i> , 2018 , 1,	15.7	5
131	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017 , 51, 355-365	2.6	17
130	Ketamine and ECT: better alone than together?. <i>Lancet Psychiatry</i> , 2017 , 4, 348-349	23.3	10
129	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. <i>Journal of Affective Disorders</i> , 2017 , 218, 277-283	6.6	30
128	A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. <i>Journal of Psychopharmacology</i> , 2017 , 31, 1190-1203	4.6	7
127	Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2017 , 82, 866-874	7.9	57
126	Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression. <i>Neuropsychopharmacology</i> , 2017 , 42, 876-885	8.7	45
125	Ketamine Treatment and Global Brain Connectivity in Major Depression. <i>Neuropsychopharmacology</i> , 2017 , 42, 1210-1219	8.7	179
124	The influence of depression on personality traits in patients with fibromyalgia: a case-control study. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 105, 13-19	2.2	2
123	Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. <i>Neurophotonics</i> , 2016 , 3, 031404	3.9	86
122	The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy. <i>Neuropsychiatric Disease and Treatment</i> , 2016 , 12, 2131-42	3.1	10
121	Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. <i>Human Brain Mapping</i> , 2016 , 37, 3214-23	5.9	87
120	Ketamine for treatment-resistant depression: recent developments and clinical applications. <i>Evidence-Based Mental Health</i> , 2016 , 19, 35-8	11.1	73
119	Using Placebo Response to Pain as a Predictor of Placebo Response in Mood Disorders. <i>Current Behavioral Neuroscience Reports</i> , 2016 , 3, 360-367	1.7	
118	Chapter 40 Transcranial Near-Infrared Light for Major Depressive Disorder 2016 , 809-824		
117	Depressive Disorders 2016 , 57-73		
116	Bipolar Disorders 2016 , 74-87		
115	Using Electroencephalography for Treatment Guidance in Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016 , 1, 411-422	3.4	30

114	Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium. <i>Focus (American Psychiatric Publishing)</i> , 2015 , 13, 94-101	1.1	
113	Anhedonia in melancholic and non-melancholic depressive disorders. <i>Journal of Affective Disorders</i> , 2015 , 184, 81-8	6.6	41
112	Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. <i>Brain Stimulation</i> , 2015 , 8, 787-94	5.1	89
111	In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. <i>Annals of the New York Academy of Sciences</i> , 2015 , 1344, 50-65	6.5	65
110	An exploratory study of responses to low-dose lithium in African Americans and Hispanics. <i>Journal of Affective Disorders</i> , 2015 , 178, 224-8	6.6	7
109	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2015 , 71, 126-33	5.2	23
108	The association of post-stroke anhedonia with salivary cortisol levels and stroke lesion in hippocampal/parahippocampal region. <i>Neuropsychiatric Disease and Treatment</i> , 2015 , 11, 233-42	3.1	9
107	Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. <i>Psychiatry Journal</i> , 2015 , 2015, 352979	2.4	59
106	Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2015 , 40, 1084-90	8.7	89
105	Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression. <i>Biological Psychiatry</i> , 2015 , 77, 285-294	7.9	201
104	The influence of depressive symptoms on quality of life after stroke: a prospective study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015 , 24, 201-9	2.8	24
103	The promise of ketamine for treatment-resistant depression: current evidence and future directions. <i>Annals of the New York Academy of Sciences</i> , 2015 , 1345, 47-58	6.5	56
102	Ketamine safety and tolerability in clinical trials for treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 247-52	4.6	136
101	Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 738-40	4.6	5
100	Tissue-specific differences in brain phosphodiesterases in late-life major depression. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 499-509	6.5	14
99	Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association. <i>Bipolar Disorders</i> , 2014 , 16, 199-203	3.8	34
98	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports. <i>Journal of Psychiatric Research</i> , 2014 , 57, 51-7	5.2	25
97	Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2014 , 15, 240	2.8	31

96	Biomarkers in major depressive disorder: the role of mass spectrometry. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 806, 545-60	3.6	12
95	A randomized controlled trial of intranasal ketamine in major depressive disorder. <i>Biological Psychiatry</i> , 2014 , 76, 970-6	7.9	277
94	Rare copy number variation in treatment-resistant major depressive disorder. <i>Biological Psychiatry</i> , 2014 , 76, 536-41	7.9	54
93	The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder. <i>Journal of Affective Disorders</i> , 2014 , 169, 144-8	6.6	14
92	Limbic system white matter microstructure and long-term treatment outcome in major depressive disorder: a diffusion tensor imaging study using legacy data. <i>World Journal of Biological Psychiatry</i> , 2014 , 15, 122-34	3.8	33
91	Cognitive-emotional training as an intervention for major depressive disorder. <i>Depression and Anxiety</i> , 2014 , 31, 699-706	8.4	41
90	Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. <i>Depression and Anxiety</i> , 2014 , 31, 335-43	8.4	220
89	Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. <i>JAMA Psychiatry</i> , 2014 , 71, 681-8	14.5	337
88	A novel application of the Intent to Attend assessment to reduce bias due to missing data in a randomized controlled clinical trial. <i>Clinical Trials</i> , 2014 , 11, 494-502	2.2	4
87	Executive function and depressive symptoms of retardation in nonelderly stroke patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014 , 36, 636-47	2.1	3
86	Feasibility of studying brain morphology in major depressive disorder with structural magnetic resonance imaging and clinical data from the electronic medical record: a pilot study. <i>Psychiatry Research - Neuroimaging</i> , 2013 , 211, 202-13	2.9	12
85	Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. <i>American Journal of Psychiatry</i> , 2013 , 170, 102-10	11.9	51
84	Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. <i>Biological Psychiatry</i> , 2013 , 74, 250-6	7.9	498
83	The Medication Recommendation Tracking Form: a novel tool for tracking changes in prescribed medication, clinical decision making, and use in comparative effectiveness research. <i>Journal of Psychiatric Research</i> , 2013 , 47, 1686-93	5.2	10
82	A mega-analysis of genome-wide association studies for major depressive disorder. <i>Molecular Psychiatry</i> , 2013 , 18, 497-511	15.1	853
81	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. <i>Psychopharmacology</i> , 2013 , 231, 481	4.7	57
80	Use of treatment services in a comparative effectiveness study of bipolar disorder. <i>Psychiatric Services</i> , 2013 , 64, 1119-26	3.3	3
79	Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. <i>American Journal of Psychiatry</i> , 2013 , 170, 1134-42	11.9	725

78	QT interval and antidepressant use: a cross sectional study of electronic health records. <i>BMJ, The</i> , 2013 , 346, f288	5.9	205
77	Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013 , 47, 26-42	2.6	49
76	Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, 51-6	4.6	24
75	A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, e636-41	4.6	58
74	Depression: Diagnosis and Treatment 2013 , 949-961		
73	The relation between mood, cognition and psychosocial functioning in psychiatric disorders. <i>European Neuropsychopharmacology</i> , 2012 , 22 Suppl 3, S499-504	1.2	44
72	Measuring severe adverse events and medication selection using a "PEER Report" for nonpsychotic patients: a retrospective chart review. <i>Neuropsychiatric Disease and Treatment</i> , 2012 , 8, 277-84	3.1	1
71	Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment - Moderate dose Use Study (LiTMUS) for bipolar disorder. <i>Clinical Trials</i> , 2012 , 9, 94-101	2.2	8
70	Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. <i>American Journal of Psychiatry</i> , 2012 , 169, 1065-72	11.9	59
69	A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). <i>Psychotherapy and Psychosomatics</i> , 2012 , 81, 87-97	9.4	99
68	Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. <i>BMJ Open</i> , 2012 , 2, e000544	3	36
67	Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. <i>CNS Spectrums</i> , 2012 , 17, 76-86	1.8	14
66	Diagnosis and treatment of major depressive disorder. <i>Neurologic Clinics</i> , 2011 , 29, 177-93, ix	4.5	26
65	Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. <i>Neurobiology of Learning and Memory</i> , 2011 , 96, 553-63	3.1	222
64	The association of major depressive episode and personality traits in patients with fibromyalgia. <i>Clinics</i> , 2011 , 66, 973-8	2.3	18
63	Retrospective chart review of a referenced EEG database in assisting medication selection for treatment of depression in patients with eating disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 529-41	3.1	6
62	Polypharmacy or medication washout: an old tool revisited. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 639-48	3.1	14
61	The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. <i>Journal of Psychiatric Research</i> , 2011 , 45, 64-75	5.2	34

60	Stroke lesion in cortical neural circuits and post-stroke incidence of major depressive episode: a 4-month prospective study. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 539-48	3.8	68
59	Electroencephalography-derived biomarkers of antidepressant response. <i>Harvard Review of Psychiatry</i> , 2011 , 19, 144-54	4.1	92
58	A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 473-9	4.6	30
57	Prevalence of incompletely penetrant Huntington@ disease alleles among individuals with major depressive disorder. <i>American Journal of Psychiatry</i> , 2010 , 167, 574-9	11.9	39
56	RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). <i>CNS Neuroscience and Therapeutics</i> , 2010 , 16, 322-5	6.8	94
55	GABA-A receptor modulators: can they offer any improvement over benzodiazepines in the treatment of anxiety disorders?. <i>CNS Neuroscience and Therapeutics</i> , 2010 , 16, 61-2	6.8	2
54	Relationship between residual symptoms of depression and self-reported cognitive impairment. <i>CNS Spectrums</i> , 2010 , 15, 46-51	1.8	20
53	Age-related changes in brain energetics and phospholipid metabolism. <i>NMR in Biomedicine</i> , 2010 , 23, 242-50	4.4	58
52	Microstructural abnormalities in subcortical reward circuitry of subjects with major depressive disorder. <i>PLoS ONE</i> , 2010 , 5, e13945	3.7	100
51	Importance of retardation and fatigue/interest domains for the diagnosis of major depressive episode after stroke: a four months prospective study. <i>Revista Brasileira De Psiquiatria</i> , 2009 , 31, 202-7	2.6	10
50	Lithium treatment -- moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. <i>Clinical Trials</i> , 2009 , 6, 637-48	2.2	36
49	Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. <i>Psychotherapy and Psychosomatics</i> , 2009 , 78, 91-7	9.4	98
48	Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. <i>American Journal of Psychiatry</i> , 2009 , 166, 702-10	11.9	804
47	Recognition of depressive symptoms by physicians. <i>Clinics</i> , 2009 , 64, 629-35	2.3	12
46	A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. <i>Contemporary Clinical Trials</i> , 2009 , 30, 205-11	2.3	42
45	Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. <i>Psychiatry Research</i> , 2009 , 169, 132-8	9.9	95
44	Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. <i>Psychiatry Research</i> , 2009 , 169, 124-31	9.9	140
43	Frontal EEG predictors of treatment outcome in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2009 , 19, 772-7	1.2	128

42	Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. <i>CNS Neuroscience and Therapeutics</i> , 2009 , 15, 309-19	6.8	35
41	Low-dose transdermal testosterone augmentation therapy improves depression severity in women. <i>CNS Spectrums</i> , 2009 , 14, 688-94	1.8	44
40	Clinical applications of neuroimaging for treating depressive disorders. <i>Psychiatry</i> , 2009 , 6, 49-51		
39	Neuroimaging and Electrophysiology Studies in Major Depressive Disorder. <i>Medical Psychiatry</i> , 2009 , 150-165		
38	Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. <i>Journal of Psychiatric Research</i> , 2008 , 43, 76-87	5.2	488
37	Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. <i>Biological Psychiatry</i> , 2008 , 63, 1127-34	7.9	134
36	Euthymic patients with bipolar disorder show decreased reward learning in a probabilistic reward task. <i>Biological Psychiatry</i> , 2008 , 64, 162-8	7.9	131
35	Cortical thickness abnormalities in cocaine addiction--a reflection of both drug use and a pre-existing disposition to drug abuse?. <i>Neuron</i> , 2008 , 60, 174-88	13.9	117
34	Treating depression in the medically ill. <i>Psychiatric Clinics of North America</i> , 2007 , 30, 77-90	3.1	33
33	Major depressive disorder and inflammatory markers in elderly patients with heart failure. <i>Psychosomatics</i> , 2007 , 48, 319-24	2.6	20
32	Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities. <i>Journal of Nervous and Mental Disease</i> , 2007 , 195, 175-8	1.8	21
31	Major depressive disorder with anger attacks and cardiovascular risk factors. <i>International Journal of Psychiatry in Medicine</i> , 2007 , 37, 99-111	1	11
30	Autonomic reactivity to induced emotion as potential predictor of response to antidepressant treatment. <i>Psychiatry Research</i> , 2007 , 151, 169-72	9.9	36
29	Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study. <i>Psychosomatics</i> , 2007 , 48, 418-25	2.6	24
28	The detection of depression in medical setting: a study with PRIME-MD. <i>Journal of Affective Disorders</i> , 2006 , 91, 11-7	6.6	51
27	The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. <i>Depression and Anxiety</i> , 2006 , 23, 178-81	8.4	42
26	Clinical characteristics of depressed patients with comorbid diabetes mellitus. <i>International Clinical Psychopharmacology</i> , 2006 , 21, 43-7	2.2	5
25	Brain white-matter hyperintensities and treatment outcome in major depressive disorder. <i>British Journal of Psychiatry</i> , 2006 , 188, 180-5	5.4	51

24	A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1754-9	4.6	149
23	Tridimensional personality questionnaire factors in major depressive disorder: relationship to anxiety disorder comorbidity and age of onset. <i>Psychotherapy and Psychosomatics</i> , 2005 , 74, 173-8	9.4	37
22	Empirical testing of two models for staging antidepressant treatment resistance. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 336-41	1.7	79
21	Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. <i>Psychosomatic Medicine</i> , 2005 , 67, 703-6	3.7	48
20	Obesity among outpatients with major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2005 , 8, 59-63	5.8	74
19	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). <i>Psychiatry Research - Neuroimaging</i> , 2005 , 140, 301-7.9	2.9	26
18	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). <i>Psychiatry Research - Neuroimaging</i> , 2005 , 140, 291-9.9	2.9	25
17	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>Focus (American Psychiatric Publishing)</i> , 2005 , 3, 69-75	1.1	1
16	An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 1038-42	4.6	43
15	Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. <i>Current Psychiatry Reports</i> , 2004 , 6, 193-201	9.1	47
14	Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. <i>European Neuropsychopharmacology</i> , 2004 , 14, 135-42	1.2	104
13	Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. <i>Psychosomatics</i> , 2004 , 45, 224-9	2.6	20
12	Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. <i>Psychosomatics</i> , 2004 , 45, 419-25	2.6	38
11	Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 467-9	1.7	10
10	Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 543-6	4.6	25
9	The impact of medical comorbidity on acute treatment in major depressive disorder. <i>American Journal of Psychiatry</i> , 2003 , 160, 2122-7	11.9	92
8	31P-Magnetic Resonance Spectroscopy and Thyroid Hormones in Major Depressive Disorder: Toward a Bioenergetic Mechanism in Depression?. <i>Harvard Review of Psychiatry</i> , 2003 , 11, 51-63	4.1	23
7	Biological predictors of treatment response in affective illness. <i>Psychiatric Clinics of North America</i> , 2003 , 26, 323-44, vii	3.1	6

6	Axis III disorders in treatment-resistant major depressive disorder. <i>Psychiatry Research</i> , 2003 , 118, 183-89.9	24
5	Serum cholesterol in treatment-resistant depression. <i>Neuropsychobiology</i> , 2003 , 47, 146-51	4 36
4	31P-magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: toward a bioenergetic mechanism in depression?. <i>Harvard Review of Psychiatry</i> , 2003 , 11, 51-63	4.1 22
3	T3 blood levels and treatment outcome in depression. <i>International Journal of Psychiatry in Medicine</i> , 2001 , 31, 367-73	1 10
2	An automated registration algorithm for measuring MRI subcortical brain structures. <i>NeuroImage</i> , 1997 , 6, 13-25	7.9 113
1	Parcellation of the human prefrontal cortex using MRI. <i>Psychiatry Research - Neuroimaging</i> , 1997 , 76, 29-40	2.9 41